Business Context and Reporting Period
Progyny, Inc. (PGNY) filed a Form 8-K on May 26, 2026, reporting a corporate action approved by its Board of Directors. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial metric disclosed is the authorization of a share repurchase program with a total value of up to $200 million, to be funded through available cash balances.
Material Changes
The material change reported is the initiation of a new share repurchase program. The company has not provided comparative financial data or changes in operational metrics versus prior periods in this document.
Guidance, Outlook, and Risks
- Repurchase Program Details: Shares may be repurchased via open market transactions or Rule 10b5-1 plans, subject to stock price and market conditions.
- Discretion: The program may be suspended or discontinued at any time at the Company's sole discretion.
- Uncertainty: The filing explicitly states there are no assurances regarding the number of shares to be repurchased or the prices at which purchases will be made.
Investor Verification Checklist
- Verify the company's current cash balance to assess the impact of the $200 million repurchase authorization on liquidity.
- Review recent quarterly reports (10-Q) or annual reports (10-K) for the most recent revenue, profit, and debt figures, as they are absent in this 8-K.
- Monitor future filings for actual execution of the share repurchase program, including volume and average price paid.